Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2961-2971

  Bishop, Kenneth D ^a,b   Olszewski, Adam J ^a,c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

epidemiology; melanoma; mucosal melanoma; ocular melanoma; period survival; radiotherapy; SEER; uveal melanoma

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ANATOMICAL VARIATION; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DATA ANALYSIS; EYE MELANOMA; EYE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MUCOSAL MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; SEX RATIO; SKIN SURGERY; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

EPIDEMIOLOGY; MELANOMA; MUCOSAL MELANOMA; OCULAR MELANOMA; PERIOD SURVIVAL; RADIOTHERAPY; SEER; UVEAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; EYE NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGED; POPULATION SURVEILLANCE; SEER PROGRAM; SKIN NEOPLASMS; SOCIAL CLASS; SURVIVAL; YOUNG ADULT;

EID: 84897987381     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28625     Document Type: Article

References (49)

1. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103: 1000-7.
2. Thoelke A, Willrodt S, Hauschild A, et al. Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment. Onkologie 2004; 27: 492-9.
3. Mihajlovic M, Vlajkovic S, Jovanovic P, et al. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012; 5: 739-53.
4. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5: e120.
5. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying)-Linked To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission, 2012.
6. NAACCR Race and Ethnicity Work Group. NAACCR guideline for enhancing Hispanic/Latino identification: revised NAACCR Hispanic/Latino identification algorithm [NHIA v2.2.1]. Springfield, IL: North American Association of Central Cancer Registries, 2011.
7. Young JL, Jr, Roffers SD, Ries LAG, et al. SEER summary staging manual-2000: codes and coding instructions. Bethesda, MD: National Cancer Institute, 2001.
8. Tiwari RC, Clegg LX, Zou Z,. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res 2006; 15: 547-69.
9. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-56.
10. Dickman PW, Adami HO,. Interpreting trends in cancer patient survival. J Intern Med 2006; 260: 103-17.
11. Brenner H, Hakulinen T,. Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision. J Clin Epidemiol 2006; 59: 570-5.
12. Perme MP, Stare J, Esteve J,. On estimation in relative survival. Biometrics 2012; 68: 113-20.
13. Roche L, Danieli C, Belot A, et al. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 2013; 132: 2359-69.
14. Rutherford MJ, Dickman PW, Lambert PC,. Comparison of methods for calculating relative survival in population-based studies. Cancer Epidemiol 2012; 36: 16-21.
15. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-51.
16. Zippin C, Lum D, Hankey BF,. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76: 2343-50.
17. Stang A, Schmidt-Pokrzywniak A, Lehnert M, et al. Population-based incidence estimates of uveal melanoma in Germany. Supplementing cancer registry data by case-control data. Eur J Cancer Prev 2006; 15: 165-70.
18. Hall HI, Jamison P, Fulton JP, et al. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol 2003; 49: 624-30.
19. Cockburn M, Swetter SM, Peng D, et al. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 2008; 59: 1081-5.
20. Micu E, Juzeniene A, Moan J,. Comparison of the time and latitude trends of melanoma incidence in anorectal region and perianal skin with those of cutaneous malignant melanoma in Norway. J Eur Acad Dermatol Venereol 2011; 25: 1444-9.
21. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer 2012; 48: 1167-75.
22. Koomen ER, de Vries E, van Kempen LC, et al. Epidemiology of extracutaneous melanoma in the Netherlands. Cancer Epidemiol Biomarkers Prev 2010; 19: 1453-9.
23. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, et al. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 2013; 6: 1230-44.
24. DeMatos P, Tyler DS, Seigler HF,. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998; 5: 733-42.
25. McLean N, Tighiouart M, Muller S,. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma. Oral Oncol 2008; 44: 1039-46.
26. Chang AE, Karnell LH, Menck HR,. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1664-78.
27. Moxley KM, Fader AN, Rose PG, et al. Malignant melanoma of the vulva: an extension of cutaneous melanoma? Gynecol Oncol 2011; 122: 612-17.
28. Hussein MR,. Extracutaneous malignant melanomas. Cancer Invest 2008; 26: 516-34.
29. Furney SJ, Turajlic S, Stamp G, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 2013; 230: 261-9.
30. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-90.
31. Cruz F, III, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63: 5761-6.
32. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005; 58: 640-4.
33. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
34. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-9.
35. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6.
36. Omholt K, Grafstrom E, Kanter-Lewensohn L, et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17: 3933-42.
37. Zebary A, Jangard M, Omholt K, et al. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer 2013; 109: 559-64.
38. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121: 257-64.
39. Becker JC, Brocker EB, Schadendorf D, et al. Imatinib in melanoma: a selective treatment option based on KIT mutation status? J Clin Oncol 2007; 25: e9.
40. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31: 3182-90.
41. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-6.
42. Wu AJ, Gomez J, Zhung JE, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol 2010; 33: 281-5.
43. Tomicic J, Wanebo HJ,. Mucosal melanomas. Surg Clin North Am 2003; 83: 237-52.
44. Bullard KM, Tuttle TM, Rothenberger DA, et al. Surgical therapy for anorectal melanoma. J Am Coll Surg 2003; 196: 206-11.
45. Ahn HJ, Na II, Park YH, et al. Role of adjuvant chemotherapy in malignant mucosal melanoma of the head and neck. Oral Oncol 2010; 46: 607-11.
46. Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013; 19: 4488-98.
47. Chang W, Lee SJ, Park S, et al. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Melanoma Res 2013; 23: 147-51.
48. Hsieh MC, Yu Q, Wu XC, et al. Evaluating factors associated with unknown SEER summary stage 2000 derived from collaborative stage at central registry level. J Registry Manag 2012; 39: 101-6.
49. Lai SM, King JB, Garimella S, et al. Effect of the staging schema on melanoma cancer reporting, 1999 to 2006. J Am Acad Dermatol 2011; 65: S95-S103.